TAK1 operates at the primary cilium in non-canonical TGFB/BMP signaling to control heart development
Preprint
Abstract
Summary: Transforming Growth Factor-Beta-Activated Kinase 1 (TAK1/MAP3K7), along with its upstream regulators TAK1-Binding Protein 2 (TAB2) and the catalytic alpha-subunit of Protein Kinase A (PKA-Cα/PRKACA), has been identified as a pivotal player in regulation of developmental processes. Haploinsufficiency of TAB2 causes Congenital Heart Disease (CHD) and rare variants in PKA-Cα and TAK1 cause cardioacrofacial dysplasia (CAFD), and Frontometaphyseal Dysplasia (FMD) and cardiospondylocarpofacial syndrome (CSCFS), respectively, rare multisystem syndromes, where CHD may appear in the clinical spectrum. We hypothesized that TAK1 plays a significant role in heart development and CHD and addressed this by genetic analysis in CHD patient cohorts and experiments in cell and animal models. Exome sequencing data from 1,471 CHD patients with extracardiac anomalies (syndromic CHD, sCHD), 2,405 patients with nonsyndromic CHD (nsCHD) and 45,082 controls showed increased burden of rare TAB2 and TAK1 variants in sCHD, but not in nsCHD. Detailed characterization of tak1 -/- and tab2 -/- zebrafish mutants revealed cardiac defects (dilated atrium, trabeculation defects, tachycardia and reduced contractility) as well as extracardiac developmental anomalies. RNA sequencing of tak1 -/- mutant hearts showed downregulation of genes encoding core cardiac transcription factors, sarcomeric proteins and extracellular matrix proteins. Experiments with cell cultures and analysis of zebrafish larvae and gastruloids indicated that TAK1 via TAB2 and PKA-Cα is activated at the primary cilium during cardiomyogenesis and that TAK1 activation at this site is enhanced by cardiomyogenic signaling molecules, including ligands of the TGFB/BMP superfamily. Consistent with these findings, CRISPR/Cas9-mediated editing of TAK1 or administration of small molecule inhibitors targeting TAK1 inhibited ciliary signaling and cardiomyocyte differentiation in vitro , while FMD-causing mutations in TAK1 reduced its ciliary localization. In conclusion, our data establishes a central role for TAK1 and its upstream regulators in cardiac development and syndromic CHD, coordinated via the primary cilium.Keywords
This publication has 59 references indexed in Scilit:
- PRKACA‐related, atrial defects‐polydactyly‐multiple congenital malformation syndrome in an Indian patientAmerican Journal of Medical Genetics Part A, 2024
- Expanding the phenotype of TAB2 variants and literature reviewAmerican Journal of Medical Genetics Part A, 2022
- The MAP3K7 gene: Further delineation of clinical characteristics and genotype/phenotype correlationsHuman Mutation, 2022
- Development of the human heartAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2020
- Head skeleton malformations in zebrafish (Danio rerio) to assess adverse effects of mixtures of compoundsArchives of Toxicology, 2018
- Heart function and hemodynamic analysis for zebrafish embryosDevelopmental Dynamics, 2017
- Mutations in MAP3K7 that Alter the Activity of the TAK1 Signaling Complex Cause Frontometaphyseal DysplasiaThe American Journal of Human Genetics, 2016
- Heterozygous Mutations in MAP3K7 , Encoding TGF-β-Activated Kinase 1, Cause Cardiospondylocarpofacial SyndromeThe American Journal of Human Genetics, 2016
- Haploinsufficiency of TAB2 Causes Congenital Heart Defects in HumansThe American Journal of Human Genetics, 2010
- Stages of embryonic development of the zebrafishDevelopmental Dynamics, 1995